This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

ETC-1001

Esperion Therapeutics, Inc.

Drug Names(s): ESP 31015, HDL elevating/Lipid Regulating Agents

Description: ETC-1001 is a small molecule that increases HDL-C levels/enhances reverse cholesterol transport. Its precise mechanism has not been disclosed.

Deal Structure: In December 2003, Esperion was acquired by Pfizer.

In May 2008, Pfizer sold Esperion to an entity funded by a syndicate of investors. Pfizer has an equity stake in the new Esperion.

Partners: Pfizer Inc.


ETC-1001 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug